Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Sep. 30, 2019 | Nov. 13, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | INTEGRATED BIOPHARMA INC | |
Entity Central Index Key | 0001016504 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 29,565,943 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2019 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Sales, net | $ 11,406 | $ 10,304 |
Cost of sales | 10,007 | 9,085 |
Gross profit | 1,399 | 1,219 |
Selling and administrative expenses | 923 | 814 |
Operating income | 476 | 405 |
Interest expense | (124) | (200) |
Change in fair value of derivative liabilities | 9 | |
Other income | 21 | |
Unrealized loss on investments | (24) | |
Total other expense, net | (127) | (191) |
Income before income taxes | 349 | 214 |
Income tax expense, net | 37 | 55 |
Net income | $ 312 | $ 159 |
Basic net income per common share (in dollars per share) | $ 0.01 | $ 0.01 |
Diluted net income per common share (in dollars per share) | $ 0.01 | $ 0.01 |
Weighted average common shares outstanding - basic (in shares) | 29,565,943 | 27,218,786 |
Add: Equivalent shares outstanding - Stock Options (in shares) | 1,158,690 | 744,818 |
Weighted average common shares outstanding - diluted (in shares) | 30,724,633 | 27,963,604 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
Current Assets: | ||
Cash | $ 525 | $ 475 |
Accounts receivable, net | 3,355 | 4,439 |
Inventories | 9,891 | 8,819 |
Other current assets | 312 | 346 |
Total current assets | 14,083 | 14,079 |
Property and equipment, net | 1,745 | 1,778 |
Operating lease right-of-use assets | 3,169 | 3,284 |
Deferred tax assets, net | 549 | 534 |
Security deposits and other assets | 95 | 115 |
Total Assets | 19,641 | 19,790 |
Current Liabilities: | ||
Advances under revolving credit facility | 4,799 | 5,834 |
Accounts payable (includes $71and $67 due to related party) | 5,106 | 3,855 |
Accrued expenses and other current liabilities | 1,110 | 1,147 |
Current portion of long term debt, net | 1,053 | 1,047 |
Current portion of operating lease liabilities | 474 | 470 |
Total current liabilities | 12,542 | 12,353 |
Operating lease liabilities | 2,702 | 2,822 |
Long term debt, net | 2,177 | 2,722 |
Total liabilities | 17,421 | 17,897 |
Commitments and Contingencies | ||
Stockholders' Equity : | ||
Common Stock, $0.002 par value; 50,000,000 shares authorized; 29,600,843 shares issued and 29,565,943 shares outstanding, respectively | 59 | 59 |
Additional paid-in capital | 50,212 | 50,197 |
Accumulated deficit | (47,952) | (48,264) |
Less: Treasury stock, at cost, 34,900 shares | (99) | (99) |
Total Stockholders' Equity | 2,220 | 1,893 |
Total Liabilities and Stockholders' Equity | $ 19,641 | $ 19,790 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
Operating lease right-of-use assets | $ 3,169 | $ 3,284 |
Accounts payable, due to related parties | 71 | 67 |
Current portion of operating lease liabilities | 474 | 470 |
Operating lease liabilities | $ 2,702 | $ 2,822 |
Common stock, par value (in dollars per share) | $ 0.002 | $ 0.002 |
Common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Common stock, shares issued (in shares) | 29,600,843 | 29,600,843 |
Common stock, shares outstanding (in shares) | 29,565,943 | 29,565,943 |
Treasury stock, shares aquired (in shares) | 34,900 | 34,900 |
Vitamin Realty LLC [Member] | ||
Operating lease right-of-use assets | $ 3,126 | $ 3,236 |
Current portion of operating lease liabilities | 454 | 450 |
Operating lease liabilities | $ 2,678 | $ 2,793 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' (Deficiency) Equity - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Treasury Stock [Member] | Total |
Balance (in shares) at Jun. 30, 2018 | 21,170,074 | 34,900 | |||
Balance at Jun. 30, 2018 | $ 42 | $ 44,773 | $ (49,952) | $ (99) | $ (5,236) |
Net income | 159 | 159 | |||
Shares issued upon conversion of CD Financial, LLC Convertible Note, net (in shares) | 8,230,769 | ||||
Shares issued upon conversion of CD Financial, LLC Convertible Note, net | $ 17 | 5,256 | 5,273 | ||
Balance (in shares) at Sep. 30, 2018 | 29,400,843 | 34,900 | |||
Balance at Sep. 30, 2018 | $ 59 | 50,029 | (49,793) | $ (99) | 196 |
Balance (in shares) at Jun. 30, 2019 | 29,600,843 | 34,900 | |||
Balance at Jun. 30, 2019 | $ 59 | 50,197 | (48,264) | $ (99) | 1,893 |
Stock compensation expense for employee stock options | 15 | 15 | |||
Net income | 312 | 312 | |||
Balance (in shares) at Sep. 30, 2019 | 29,600,843 | 34,900 | |||
Balance at Sep. 30, 2019 | $ 59 | $ 50,212 | $ (47,952) | $ (99) | $ 2,220 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Cash flows provided by operating activities: | ||
Net income | $ 312 | $ 159 |
Adjustments to reconcile net income to net cash from operating activities: | ||
Depreciation and amortization | 91 | 91 |
Amortization of operating lease right-of-use assets | 116 | 112 |
Stock based compensation | 15 | |
Change in deferred tax assets | (5) | 31 |
Unrealized loss on investments | 24 | |
Other, net | 5 | 8 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 1,084 | 415 |
Inventories | (1,073) | (1,858) |
Other current assets | 8 | |
Security deposits and other assets | 18 | (52) |
Accounts payable | 1,251 | 1,861 |
Accrued expenses and other liabilities | (37) | (70) |
Operating lease obligations | (116) | (112) |
Net cash provided by operating activities | 1,685 | 593 |
Cash flows from investing activities: | ||
Purchase of property and equipment | (58) | (18) |
Cash contribution in AgroSport LLC | (8) | |
Net cash used in investing activities | (58) | (26) |
Cash flows from financing activities: | ||
Advances under revolving credit facility | 11,040 | 10,204 |
Repayments of advances under revolving credit facility | (12,075) | (10,400) |
Repayments under term note payables | (482) | (184) |
Repayments under finance lease obligations | (60) | (50) |
Net cash used in financing activities | (1,577) | (430) |
Net increase in cash | 50 | 137 |
Cash at beginning of period | 475 | 228 |
Cash at end of period | 525 | 365 |
Interest paid | 123 | 201 |
Income taxes paid | $ 2 |
Note 1 - Principles of Consolid
Note 1 - Principles of Consolidation and Basis of Presentation | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2019 ( 10 June 30, 2019 not three September 30, 2019 not June 30, 2020 Reclassifications. Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Green Envy, FiberCal, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. Accounting Policies Accounting Pronouncements Recently Adopted In October, 2016, No. 2016 16, 740 July 1, 2019. not In July 2017, 2017 11, 260 480 815 July 1, 2019 June 30, 2020, not Aside from the adoption of ASUs, as described above, there have been no 2020 10 June 30, 2019. Significant Accoun ting P olicies Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable were not three September 30, 2019 2018: Three Months Ended September 30, 2019 2018 Anti-dilutive stock options 50,000 150,000 Total anti-dilutive shares 50,000 150,000 |
Note 2 - Inventories
Note 2 - Inventories | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | Note 2 . Inventories Inventories are stated at the lower of cost or net realizable value using the first first September 30, June 30, 2019 2019 Raw materials $ 6,642 $ 4,550 Work-in-process 1,823 2,325 Finished goods 1,426 1,944 Total $ 9,891 $ 8,819 |
Note 3 - Property and Equipment
Note 3 - Property and Equipment, Net | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 3 . Property and Equipment, net Property and equipment, net consists of the following: September 30, June 30, 2019 2019 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,282 1,282 Machinery and equipment 6,338 6,280 Transportation equipment 6 6 8,876 8,818 Less: Accumulated depreciation and amortization (7,131 ) (7,040 ) Total $ 1,745 $ 1,778 Depreciation and amortization expense recorded on property and equipment for the three September 30, 2019 2018 $91 $66, |
Note 4 - Senior Credit Facility
Note 4 - Senior Credit Facility and Other Long Term Debt | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 4 . Senior Credit Facility and other Long Term Debt As of September 30, 2019 June 30, 2019, Principal Amount Interest Rate Maturity Date As of September 30, 2019 As of June 30, 2019 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 4,799 $ 5,834 * 5/15/2024 Installment Note with PNC Bank 3,069 3,542 * 5/15/2024 Installment Note with PNC Equipment Finance - 8 4.57 % 7/29/2019 Capitalized lease obligations 209 269 4.01% - 9.38 % 11/01/2019 - 2/1/2021 Total outstanding debt 8,077 9,653 Less: Revolving Advances (4,799 ) (5,834 ) Prepaid financing costs (48 ) (50 ) Current portion of long term debt, net (1,053 ) (1,047 ) Long term debt, net $ 2,177 $ 2,722 * See table below SENIOR CREDIT FACILITY On May 15, 2019, June 27, 2012, February 19, 2016 May 15, 2019. The Amended Loan Agreement provides for a total of $11,585 $8,000 $3,585 2.50%. 3.00%. As of September 30, 2019 June 30, 2019, $4,000 $4,250 $2,674 $3,455 September 30, 2019 June 30, 2019 2.50% 3.00% September 30, June 30, 2019 2019 Revolving Credit Facility: Base Rate Interest 5.00 % 5.50 % Eurodollar Rate 4.554 % 4.881 % Term Loan: Base Rate Interest 5.25 % 5.75 % Eurodollar Rate 5.05363% and 5.04588% 5.381% and 5.3838% Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. May 15, 2024 ( The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four 84 first eighty-three 83 $43, first June, 2019, first The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of ( x $8,000 85%, 75%, 85% one may The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five 25% June 30, 2016, not one hundred twenty 120 September 30, 2019, 25% June 30, 2016. In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC. OTHER LONG TERM DEBT Capitalized Lease Obligations. November 1, 2019, December 22, 2017 $143, $6 6.56%. |
Note 5 - Significant Risks and
Note 5 - Significant Risks and Uncertainties | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 5. ( a ) Major Customers. three September 30, 2019 2018, 91% 89% two two 66% 29% 61% 29% three September 30, 2019 2018, two 87% 88% September 30 June 30, 2019, 10% ( b ) Other Business Risks. 72% September 1, 2018 August 31, 2021. |
Note 6 - Leases and Other Commi
Note 6 - Leases and Other Commitments and Contingencies | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 6. (a) Leases. 1 8 The components of lease expense for the three September 30, 2019 2018, 2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 135 $ 39 $ 174 $ 141 $ 22 $ 163 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 27 $ 27 $ - $ 17 $ 17 Interest on operating lease liabilities - 5 5 - 4 4 Total finance lease cost $ - $ 32 $ 32 $ - $ 21 $ 21 Operating Lease Liabilities Related Party Operating L e ase Liabilities . 100% January 5, 2012, second 74,898 76,161 January 31, 2026. $533, May 19, 2014, January 5, 2012, 2,700 January 31, 2019 June 1, 2024. $27 Rent expense, lease amortization costs and interest expense for the three September 30, 2019 2018 $207 $202 September 30, 2019 June 30, 2019, $71 $67, $3,132 $3,243 September 30, 2019 June 30, 2019, Other Operating Lease Liabilities . May, 2023, As of September 30, 2019, Right-of-use Assets Current Portion of Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,126 $ 454 $ 2,678 $ 3,527 Machinery and equipment leases 24 11 13 25 Office equipment leases 19 9 11 20 $ 3,169 $ 474 $ 2,702 $ 3,572 As of June 30, 2019, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,236 $ 450 $ 2,793 $ 3,668 Machinery and equipment leases 26 11 15 27 Office equipment leases 22 9 14 24 $ 3,284 $ 470 $ 2,822 $ 3,719 As of September 30, 2019 June 30, 2019, 3.75% 3.76% 6.1 6.4 Supplemental cash flows information related to leases for the three September 30, 2019, Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 141 $ 24 $ 165 Operating cash flows from finance leases - 5 5 Financing cash flows from finance lease obligations - 60 60 Supplemental cash flows information related to leases for the three September 30, 2018, Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 94 $ 24 $ 118 Operating cash flows from finance leases - 4 4 Financing cash flows from finance lease obligations - 50 50 The Company did not three September 30, 2019. Maturities of operating lease liabilities as of September 30, 2019 Operating Related Party Capitalized Lease Operating Lease Lease Year ending June 30, Commitment Commitment Obligations Total 2020, remaining $ 27 $ 424 $ 144 $ 595 2021 21 565 90 676 2022 8 565 - 573 2023 - 565 - 565 2024 - 563 - 563 2025 - 533 - 533 Thereafter - 311 - 311 Total minimum lease payments 56 3,526 234 3,816 Imputed interest (2 ) (394 ) (25 ) (421 ) Total $ 54 $ 3,132 $ 209 $ 3,395 Total rent expense, lease amortization costs and interest expense, including real estate taxes and maintenance charges, was approximately $257 $245 three September 30, 2019 2018, ( b ) Legal Proceedings. The Company is subject, from time to time, to claims by third |
Note 7 - Related Party Transact
Note 7 - Related Party Transactions | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 7. See Note 6 |
Note 8 - Segment Information an
Note 8 - Segment Information and Disaggregated Revenue | 3 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | Note 8. and Disaggregated Revenue The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments. The Company has divided its operations into three three September 30, 2019 2018 $1,053 $1,239, Financial information relating to the three September 30, 2019 2018 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract 2019 $ 9,974 $ 1,010 $ 10,984 $ 1,250 $ 90 $ 58 Manufacturing 2018 8,655 1,197 9,852 1,083 65 18 Branded Proprietary 2019 2 10 12 (3 ) - - Products 2018 71 7 78 21 - - Other Nutraceutical 2019 377 33 410 152 1 - Businesses 2018 339 35 374 115 1 - Total Company 2019 10,353 1,053 11,406 1,399 91 58 2018 9,065 1,239 10,304 1,219 66 18 Total Assets as of September 30, June 30, 2019 2019 Contract Manufacturing $ 17,575 $ 17,580 Branded Proprietary Products 413 427 Other Nutraceutical Businesses 1,653 1,783 Total Company $ 19,641 $ 19,790 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2019 ( 10 June 30, 2019 not three September 30, 2019 not June 30, 2020 |
Reclassification, Policy [Policy Text Block] | Reclassifications. |
Nature of Operations [Policy Text Block] | Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Green Envy, FiberCal, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. |
New Accounting Pronouncements, Policy [Policy Text Block] | Accounting Pronouncements Recently Adopted In October, 2016, No. 2016 16, 740 July 1, 2019. not In July 2017, 2017 11, 260 480 815 July 1, 2019 June 30, 2020, not Aside from the adoption of ASUs, as described above, there have been no 2020 10 June 30, 2019. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. |
Lessee, Leases [Policy Text Block] | Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. |
Earnings Per Share, Policy [Policy Text Block] | Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable were not three September 30, 2019 2018: Three Months Ended September 30, 2019 2018 Anti-dilutive stock options 50,000 150,000 Total anti-dilutive shares 50,000 150,000 |
Note 1 - Principles of Consol_2
Note 1 - Principles of Consolidation and Basis of Presentation (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended September 30, 2019 2018 Anti-dilutive stock options 50,000 150,000 Total anti-dilutive shares 50,000 150,000 |
Note 2 - Inventories (Tables)
Note 2 - Inventories (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | September 30, June 30, 2019 2019 Raw materials $ 6,642 $ 4,550 Work-in-process 1,823 2,325 Finished goods 1,426 1,944 Total $ 9,891 $ 8,819 |
Note 3 - Property and Equipme_2
Note 3 - Property and Equipment, Net (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | September 30, June 30, 2019 2019 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,282 1,282 Machinery and equipment 6,338 6,280 Transportation equipment 6 6 8,876 8,818 Less: Accumulated depreciation and amortization (7,131 ) (7,040 ) Total $ 1,745 $ 1,778 |
Note 4 - Senior Credit Facili_2
Note 4 - Senior Credit Facility and Other Long Term Debt (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Principal Amount Interest Rate Maturity Date As of September 30, 2019 As of June 30, 2019 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 4,799 $ 5,834 * 5/15/2024 Installment Note with PNC Bank 3,069 3,542 * 5/15/2024 Installment Note with PNC Equipment Finance - 8 4.57 % 7/29/2019 Capitalized lease obligations 209 269 4.01% - 9.38 % 11/01/2019 - 2/1/2021 Total outstanding debt 8,077 9,653 Less: Revolving Advances (4,799 ) (5,834 ) Prepaid financing costs (48 ) (50 ) Current portion of long term debt, net (1,053 ) (1,047 ) Long term debt, net $ 2,177 $ 2,722 * See table below |
Schedule of Debt Interest Rates [Table Text Block] | September 30, June 30, 2019 2019 Revolving Credit Facility: Base Rate Interest 5.00 % 5.50 % Eurodollar Rate 4.554 % 4.881 % Term Loan: Base Rate Interest 5.25 % 5.75 % Eurodollar Rate 5.05363% and 5.04588% 5.381% and 5.3838% |
Note 6 - Leases and Other Com_2
Note 6 - Leases and Other Commitments and Contingencies (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Lease, Cost [Table Text Block] | 2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 135 $ 39 $ 174 $ 141 $ 22 $ 163 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 27 $ 27 $ - $ 17 $ 17 Interest on operating lease liabilities - 5 5 - 4 4 Total finance lease cost $ - $ 32 $ 32 $ - $ 21 $ 21 |
Leases and Remaining Commitments [Table Text Block] | Right-of-use Assets Current Portion of Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,126 $ 454 $ 2,678 $ 3,527 Machinery and equipment leases 24 11 13 25 Office equipment leases 19 9 11 20 $ 3,169 $ 474 $ 2,702 $ 3,572 Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,236 $ 450 $ 2,793 $ 3,668 Machinery and equipment leases 26 11 15 27 Office equipment leases 22 9 14 24 $ 3,284 $ 470 $ 2,822 $ 3,719 |
Supplemental Cash Flow Information, Leases [Table Text Block] | Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 141 $ 24 $ 165 Operating cash flows from finance leases - 5 5 Financing cash flows from finance lease obligations - 60 60 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 94 $ 24 $ 118 Operating cash flows from finance leases - 4 4 Financing cash flows from finance lease obligations - 50 50 |
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block] | Operating Related Party Capitalized Lease Operating Lease Lease Year ending June 30, Commitment Commitment Obligations Total 2020, remaining $ 27 $ 424 $ 144 $ 595 2021 21 565 90 676 2022 8 565 - 573 2023 - 565 - 565 2024 - 563 - 563 2025 - 533 - 533 Thereafter - 311 - 311 Total minimum lease payments 56 3,526 234 3,816 Imputed interest (2 ) (394 ) (25 ) (421 ) Total $ 54 $ 3,132 $ 209 $ 3,395 |
Note 8 - Segment Information _2
Note 8 - Segment Information and Disaggregated Revenue (Tables) | 3 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract 2019 $ 9,974 $ 1,010 $ 10,984 $ 1,250 $ 90 $ 58 Manufacturing 2018 8,655 1,197 9,852 1,083 65 18 Branded Proprietary 2019 2 10 12 (3 ) - - Products 2018 71 7 78 21 - - Other Nutraceutical 2019 377 33 410 152 1 - Businesses 2018 339 35 374 115 1 - Total Company 2019 10,353 1,053 11,406 1,399 91 58 2018 9,065 1,239 10,304 1,219 66 18 |
Reconciliation of Assets from Segment to Consolidated [Table Text Block] | Total Assets as of September 30, June 30, 2019 2019 Contract Manufacturing $ 17,575 $ 17,580 Branded Proprietary Products 413 427 Other Nutraceutical Businesses 1,653 1,783 Total Company $ 19,641 $ 19,790 |
Note 1 - Principles of Consol_3
Note 1 - Principles of Consolidation and Basis of Presentation - Antidilutive Securities Excluded From Weighted Average Diluted Common Shares Outstanding (Details) - shares | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Anti-dilutive shares (in shares) | 50,000 | 150,000 |
Share-based Payment Arrangement, Option [Member] | ||
Anti-dilutive shares (in shares) | 50,000 | 150,000 |
Note 2 - Inventories - Inventor
Note 2 - Inventories - Inventories (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
Raw materials | $ 6,642 | $ 4,550 |
Work-in-process | 1,823 | 2,325 |
Finished goods | 1,426 | 1,944 |
Total | $ 9,891 | $ 8,819 |
Note 3 - Property and Equipme_3
Note 3 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Depreciation, Total | $ 91 | $ 66 |
Note 3 - Property and Equipme_4
Note 3 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2018 |
Property and equipment, gross | $ 8,876 | $ 8,818 | |
Less: Accumulated depreciation and amortization | (7,131) | (7,040) | |
Total | 1,745 | $ 1,778 | 1,778 |
Land and Building [Member] | |||
Property and equipment, gross | 1,250 | 1,250 | |
Leasehold Improvements [Member] | |||
Property and equipment, gross | 1,282 | 1,282 | |
Machinery and Equipment [Member] | |||
Property and equipment, gross | 6,338 | 6,280 | |
Transportation Equipment [Member] | |||
Property and equipment, gross | $ 6 | $ 6 |
Note 4 - Senior Credit Facili_3
Note 4 - Senior Credit Facility and Other Long Term Debt (Details Textual) - USD ($) $ in Thousands | May 15, 2019 | Dec. 22, 2017 | Sep. 30, 2019 | Jun. 30, 2019 |
Capital Lease Obligations, Total | $ 209 | $ 269 | ||
First American Equipment Finance [Member] | ||||
Capital Lease Obligations, Total | $ 143 | |||
Sale Leaseback Transaction, Monthly Rental Payments | $ 6 | |||
Sale Leaseback Transaction, Imputed Interest Rate | 6.56% | |||
Amended Loan Agreement [Member] | ||||
Senior Notes, Total | $ 11,585 | |||
Debt Instrument, Debt Default, Interest Rate Basic Spread | 2.00% | |||
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow | 25.00% | |||
Amended Loan Agreement [Member] | Term Loan [Member] | ||||
Debt Instrument, Face Amount | $ 3,585 | |||
Loans Payable, Noncurrent, Total | $ 2,674 | 3,455 | ||
Number of Consecutive Monthly Installments | 84 | |||
Number of Consecutive Monthly Installments, Fixed Amount | 83 | |||
Debt Instrument, Periodic Payment, Total | $ 43 | |||
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow | 25.00% | |||
Amended Loan Agreement [Member] | Term Loan [Member] | Eurodollar [Member] | ||||
Debt Instrument, Basis Spread on Variable Rate | 3.00% | |||
Amended Loan Agreement [Member] | Term Loan [Member] | Base Rate [Member] | ||||
Debt Instrument, Basis Spread on Variable Rate | 3.00% | |||
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | ||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 8,000 | |||
Long-term Line of Credit, Total | $ 4,000 | $ 4,250 | ||
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance | $ 8,000,000 | |||
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate | 85.00% | |||
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate | 75.00% | |||
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate | 85.00% | |||
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Eurodollar [Member] | ||||
Debt Instrument, Basis Spread on Variable Rate | 2.50% | |||
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | ||||
Debt Instrument, Basis Spread on Variable Rate | 2.50% |
Note 4 - Senior Credit Facili_4
Note 4 - Senior Credit Facility and Other Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Sep. 30, 2019 | Jun. 30, 2019 | ||
Capitalized lease obligations | $ 209 | $ 269 | |
Total outstanding debt | 8,077 | 9,653 | |
Prepaid financing costs | (48) | (50) | |
Current portion of long term debt, net | (1,053) | (1,047) | |
Long term debt, net | 2,177 | 2,722 | |
Convertible Debt [Member] | |||
Current portion of long term debt, net | $ (1,053) | (1,047) | |
Minimum [Member] | |||
Capitalized lease obligations, interest rate | 4.01% | ||
Capitalized lease obligations, maturity start date | Nov. 1, 2019 | ||
Maximum [Member] | |||
Capitalized lease obligations, interest rate | 9.38% | ||
Capitalized lease obligations, maturity end date | Feb. 1, 2021 | ||
Revolving Advances [Member] | |||
Notes Payable | $ 4,799 | 5,834 | |
Interest Rate | [1] | ||
Maturity Date | May 15, 2024 | ||
Less: Revolving Advances | $ (4,799) | (5,834) | |
Installment Note with PNC Bank [Member] | |||
Notes Payable | $ 3,069 | 3,542 | |
Interest Rate | [1] | ||
Maturity Date | May 15, 2024 | ||
PNC Equipment Finance LLC [Member] | |||
Notes Payable | $ 8 | ||
Interest Rate | 4.57% | ||
Maturity Date | Jul. 29, 2019 | ||
[1] | See table below |
Note 4 - Senior Credit Facili_5
Note 4 - Senior Credit Facility and Other Long Term Debt - Interest Rates (Details) | Sep. 30, 2019 | Jun. 30, 2019 |
Revolving Credit Facility [Member] | Base Rate [Member] | ||
Interest rate | 5.00% | 5.50% |
Revolving Credit Facility [Member] | Eurodollar [Member] | ||
Interest rate | 4.554% | 4.881% |
Term Loan [Member] | Base Rate [Member] | ||
Interest rate | 5.25% | 5.75% |
Term Loan [Member] | Eurodollar [Member] | Minimum [Member] | ||
Interest rate | 5.05363% | 5.381% |
Term Loan [Member] | Eurodollar [Member] | Maximum [Member] | ||
Interest rate | 5.04588% | 5.3838% |
Note 5 - Significant Risks an_2
Note 5 - Significant Risks and Uncertainties (Details Textual) | 3 Months Ended | 12 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | Jun. 30, 2019 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | |||
Number of Major Customers | 2 | 2 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Contract Manufacturing [Member] | |||
Number of Major Customers | 2 | 2 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | |||
Concentration Risk, Percentage | 91.00% | 89.00% | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member] | |||
Concentration Risk, Percentage | 66.00% | 61.00% | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member] | |||
Concentration Risk, Percentage | 29.00% | 29.00% | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | |||
Concentration Risk, Percentage | 2.00% | 2.00% | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | |||
Concentration Risk, Percentage | 87.00% | 88.00% | |
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member] | |||
Concentration Risk, Percentage | 72.00% |
Note 6 - Leases and Other Com_3
Note 6 - Leases and Other Commitments and Contingencies (Details Textual) $ in Thousands | May 19, 2014USD ($)ft² | Jan. 05, 2012USD ($)ft² | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Jun. 30, 2019USD ($) |
Operating Leases, Rent Expense, Net, Total | $ 257 | $ 245 | |||
Unrelated Party [Member] | |||||
Operating Lease, Liability, Total | $ 54 | ||||
Lessee, Operating Lease, Discount Rate | 3.75% | 3.76% | |||
Operating Lease, Weighted Average Remaining Lease Term | 6 years 36 days | 6 years 146 days | |||
Manhattan Drug Company [Member] | |||||
Payments for Rent | $ 533 | ||||
AgroLabs [Member] | |||||
Area of Real Estate Property | ft² | 2,700 | ||||
Payments for Rent | $ 27 | ||||
Chairman, Chief Executive Office and Major Stockholder [Member] | |||||
Percent of Ownership for Warehouse and Office Facilities Leased | 100.00% | ||||
Vitamin Realty LLC [Member] | |||||
Operating Leases, Rent Expense, Net, Total | $ 207 | $ 202 | |||
Due to Related Parties, Total | 71 | $ 67 | |||
Operating Lease, Liability, Total | $ 3,132 | $ 3,243 | |||
Minimum [Member] | |||||
Lessee, Lease, Term of Contract | 1 year | ||||
Minimum [Member] | Manhattan Drug Company [Member] | |||||
Area of Real Estate Property | ft² | 74,898 | ||||
Maximum [Member] | |||||
Lessee, Lease, Term of Contract | 8 years | ||||
Maximum [Member] | Manhattan Drug Company [Member] | |||||
Area of Real Estate Property | ft² | 76,161 |
Note 6 - Leases and Other Com_4
Note 6 - Leases and Other Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Operating lease costs | $ 174 | $ 163 |
Amortization of right-of use assets | 27 | 17 |
Interest on operating lease liabilities | 5 | 4 |
Total finance lease cost | 32 | 21 |
Unrelated Party [Member] | ||
Operating lease costs | 39 | 22 |
Amortization of right-of use assets | 27 | 17 |
Interest on operating lease liabilities | 5 | 4 |
Total finance lease cost | 32 | 21 |
Vitamin Realty LLC [Member] | ||
Operating lease costs | 135 | 141 |
Amortization of right-of use assets | ||
Interest on operating lease liabilities | ||
Total finance lease cost |
Note 6 - Leases and Other Com_5
Note 6 - Leases and Other Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
Operating lease right-of-use assets | $ 3,169 | $ 3,284 |
Current portion operating lease obligations | 474 | 470 |
Operating lease obligations | 2,702 | 2,822 |
Remaining cash commitment | 3,572 | 3,719 |
Machinery and Equipment Leases [Member] | ||
Operating lease right-of-use assets | 24 | 26 |
Current portion operating lease obligations | 11 | 11 |
Operating lease obligations | 13 | 15 |
Remaining cash commitment | 25 | 27 |
Office Equipment Leases [Member] | ||
Operating lease right-of-use assets | 19 | 22 |
Current portion operating lease obligations | 9 | 9 |
Operating lease obligations | 11 | 14 |
Remaining cash commitment | 20 | 24 |
Vitamin Realty LLC [Member] | ||
Operating lease right-of-use assets | 3,126 | 3,236 |
Current portion operating lease obligations | 454 | 450 |
Operating lease obligations | 2,678 | 2,793 |
Remaining cash commitment | $ 3,527 | $ 3,668 |
Note 6 - Leases and Other Com_6
Note 6 - Leases and Other Commitments and Contingencies - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Operating cash flows from operating leases | $ 165 | $ 118 |
Operating cash flows from finance leases | 5 | 4 |
Financing cash flows from finance lease obligations | 60 | 50 |
Unrelated Party [Member] | ||
Operating cash flows from operating leases | 24 | 24 |
Operating cash flows from finance leases | 5 | 4 |
Financing cash flows from finance lease obligations | 60 | 50 |
Vitamin Realty LLC [Member] | ||
Operating cash flows from operating leases | 141 | 94 |
Operating cash flows from finance leases | ||
Financing cash flows from finance lease obligations |
Note 6 - Leases and Other Com_7
Note 6 - Leases and Other Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
2020, remaining capital lease | $ 144 | |
2020, remaining total | 595 | |
2021, Capital Lease Obligation | 90 | |
2021, Total | 676 | |
2022, Capital Lease Obligation | ||
2022, Total | 573 | |
2023, Capital Lease Obligation | ||
2023, Total | 565 | |
2024, Capital Lease Obligation | ||
2024, Total | 563 | |
2025, Capital Lease Obligation | ||
2025, Total | 533 | |
Thereafter, Capital Lease Obligation | ||
Thereafter, Total | 311 | |
Total minimum lease payments, Capital Lease Obligation | 234 | |
Total minimum lease payments, Total | 3,816 | |
Imputed interest, Capital Lease Obligation | (25) | |
Imputed interest, Total | (421) | |
Total, Capital Lease Obligation | 209 | |
Total | 3,395 | |
Vitamin Realty LLC [Member] | ||
2020, remaining operating lease | 424 | |
2021, Operating Lease | 565 | |
2022, Operating Lease | 565 | |
2023, Operating Lease | 565 | |
2024, Operating Lease | 563 | |
2025, Operating Lease | 533 | |
Thereafter, Operating Lease | 311 | |
Total minimum lease payments, Operating Lease | 3,526 | |
Imputed interest, Operating Lease | (394) | |
Total, Operating Lease | 3,132 | $ 3,243 |
Unrelated Party [Member] | ||
2020, remaining operating lease | 27 | |
2021, Operating Lease | 21 | |
2022, Operating Lease | 8 | |
2023, Operating Lease | ||
2024, Operating Lease | ||
2025, Operating Lease | ||
Thereafter, Operating Lease | ||
Total minimum lease payments, Operating Lease | 56 | |
Imputed interest, Operating Lease | (2) | |
Total, Operating Lease | $ 54 |
Note 8 - Segment Information _3
Note 8 - Segment Information and Disaggregated Revenue (Details Textual) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | |
Number of Reportable Segments | 3 | |
Europe and Canada [Member] | ||
Revenues, Total | $ 1,053 | $ 1,239 |
Note 8 - Segment Information _4
Note 8 - Segment Information and Disaggregated Revenue - Operations by Business Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Sales, net | $ 11,406 | $ 10,304 |
Gross Profit | 1,399 | 1,219 |
Depreciation | 91 | 66 |
Capital Expenditures | 58 | 18 |
Contract Manufacturing [Member] | ||
Sales, net | 10,984 | 9,852 |
Gross Profit | 1,250 | 1,083 |
Depreciation | 90 | 65 |
Capital Expenditures | 58 | 18 |
Branded Proprietary Products [Member] | ||
Sales, net | 12 | 78 |
Gross Profit | (3) | 21 |
Depreciation | ||
Capital Expenditures | ||
Other Nutraceutical Business [Member] | ||
Sales, net | 410 | 374 |
Gross Profit | 152 | 115 |
Depreciation | 1 | 1 |
Capital Expenditures | ||
UNITED STATES | ||
Sales, net | 10,353 | 9,065 |
UNITED STATES | Contract Manufacturing [Member] | ||
Sales, net | 9,974 | 8,655 |
UNITED STATES | Branded Proprietary Products [Member] | ||
Sales, net | 2 | 71 |
UNITED STATES | Other Nutraceutical Business [Member] | ||
Sales, net | 377 | 339 |
Non-US [Member] | ||
Sales, net | 1,053 | 1,239 |
Non-US [Member] | Contract Manufacturing [Member] | ||
Sales, net | 1,010 | 1,197 |
Non-US [Member] | Branded Proprietary Products [Member] | ||
Sales, net | 10 | 7 |
Non-US [Member] | Other Nutraceutical Business [Member] | ||
Sales, net | $ 33 | $ 35 |
Note 8 - Segment Information _5
Note 8 - Segment Information and Disaggregated Revenue - Total Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jun. 30, 2019 |
Total Assets | $ 19,641 | $ 19,790 |
Contract Manufacturing [Member] | ||
Total Assets | 17,575 | 17,580 |
Branded Proprietary Products [Member] | ||
Total Assets | 413 | 427 |
Other Nutraceutical Business [Member] | ||
Total Assets | $ 1,653 | $ 1,783 |